文献速递药物不良反应与药物警戒

生物类似药在肿瘤学中的现状

Current Status of Biosimilars in Oncology.
PubMed 文献 · Drugs · 2017-01-01

本文讨论血液肿瘤领域生物类似药的基本原理、临床开发现状、医护人员接受趋势及未来挑战。自2005年欧洲指南发布后约20种生物类似药进入欧洲市场,2015年以来美国批准4种;欧洲数据提示纳入生物类似药可带来30-45%的成本节约,但实际节省取决于生物类似药进入成本及原研药定价反应。

要点

  • 欧洲数据提示生物类似药纳入医疗体系可带来30-45%成本节约。
  • 医护人员对生物类似药安全性和疗效的担忧通过教育项目已逐渐降低。
  • 未来需全球统一命名、监管要求和药物警戒项目以提升接受度和安全性。

核心结论

  • 生物类似药在肿瘤学中的应用有望节约成本,但真实节省取决于生物类似药进入成本及原研药定价反应。
  • 医护人员对生物类似药安全性和疗效的担忧通过积极教育项目已逐渐减少。
  • 未来需全球统一命名、监管要求和药物警戒项目以改善生物类似药的全球接受度和安全性。

研究设计与样本

  • 本文为综述,讨论血液肿瘤领域生物类似药的基本原理、临床开发现状、医护人员接受趋势及未来挑战。

主要发现

  • 自2005年原始批准指南发布以来,约20种生物类似药进入欧洲市场;自2015年以来美国批准4种生物类似药。
  • 来自生物类似药市场进入率最高的欧洲国家的数据提示,将生物类似药纳入医疗体系可能带来30-45%的成本节约。

临床怎么用

  • 在肿瘤治疗中可考虑纳入生物类似药以潜在节约成本,但需关注原研药定价反应对实际节省的影响。
  • 通过教育项目可降低医护人员对生物类似药安全性和疗效的担忧,促进采纳。
  • 关注生物类似药全球命名、监管要求和药物警戒项目的标准化进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Four medicinal cancer biological blockbusters will end their patent lifespan by 2020. It is estimated that the total market for cancer biologicals will reach approximately US$68 billion at that time. Approximately 20 biosimilars have entered the European market since the launch of the original approval guidelines in 2005, and four biosimilars have been approved in the USA since 2015. Data from European countries with the highest market entrance of biosimilars suggest that the incorporation of biosimilars into healthcare systems worldwide may result in a 30-45% cost savings. Initial levels of apprehension expressed by healthcare providers regarding the safety and efficacy of integrating biosimilars into the treatment of cancer patients have gradually decreased through active educational programs. The trust generated by regulatory agencies and drug manufacturers will ultimately make the adoption of biosimilars by healthcare providers and patients a smooth process. Future efforts to improve on the global acceptance and safety of biosimilars must include standardization of naming, regulatory requirements, and pharmacovigilance programs worldwide. High expectations are being placed on the cost savings, safety, and efficacy of these products. The entry costs for biosimilars and the pricing reaction of their originator products will determine the true savings by troubled health systems in dire need of cost cuts. This article discusses basic principles of biosimilars in hematology and oncology, the current status of their clinical development, and trends of acceptance by healthcare providers, and provides insight into potential future challenges.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Camacho LH. Current Status of Biosimilars in Oncology. Drugs. 2017. PMID: 28477160. doi:10.1007/s40265-017-0743-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。